• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Basic Materials·JUBLINGREA.NS
Share

Jubilant Ingrevia Limited Stocks

₹ 724.05Last Updated 14.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

₹ 1.19B

₹ 724.05
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Somewhat favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Jubilant Ingrevia Limited, established in 2019 and based in Noida, India, is a global supplier of life science products and comprehensive solutions. The company's operations are divided into three core divisions: Specialty Chemicals, Nutrition & Health Solutions, and Life Science Chemicals. The Specialty Chemicals segment delivers a variety of specialized ingredients, fine chemicals, and crop protection agents, in addition to offering custom development and manufacturing (CDMO) services. Its Nutrition & Health Solutions division focuses on ingredients for both human and animal nutrition and well-being. Meanwhile, the Life Science Chemicals segment provides crucial life science components and a range of specialized ethanol products. Jubilant Ingrevia's extensive portfolio encompasses numerous chemical offerings, including a broad spectrum of pyridine derivatives (such as picolines, cyanopyridines, and various substituted pyridines), essential vitamins like B3 and riboflavin phosphate sodium, and nutritional compounds like premixes and antioxidants. They also produce industrial chemicals like acetic anhydride, ethyl acetate, and various alcohols (absolute alcohol, ethanol), alongside biocompost and gas mixtures. Furthermore, the company supplies a wide array of animal health and nutrition additives, including mineral premixes, stress regulators, amino acids, herbal growth promoters, toxin binders, and enzymes. Beyond its product range, Jubilant Ingrevia offers specialized services in chemical synthesis, covering everything from initial route design and process optimization to scaling up production and commercial manufacturing of intermediates. The company serves a diverse client base across the pharmaceutical, nutrition, agrochemical, consumer goods, and industrial sectors. Originally incorporated as Jubilant LSI Limited, the company adopted its current name, Jubilant Ingrevia Limited, in October 2020.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'expens

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of JUBLINGREA.NS is 880 and suggests 20.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 20:45

"She has more lives than a cat": An investor from *The Short Game* on IBM's collapse

15.07.2026 20:22

Morgan Stanley's profits soared thanks to SpaceX's IPO and revenue from stock trading

15.07.2026 19:54

Sales at Cartier's parent company were twice as strong as expected. This bolstered the luxury market

15.07.2026 19:06

Oppenheimer withdrew its recommendation to buy IBM stock following its historic plunge

15.07.2026 18:44

Kaspi.kz has completed the acquisition of Turkey's Rabobank

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026